Royalty Pharma plc Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Royalty Pharma plc quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Royalty Pharma plc Operating Income (Loss) for the quarter ending September 30, 2024 was $735M, a 385% increase year-over-year.
  • Royalty Pharma plc Operating Income (Loss) for the twelve months ending September 30, 2024 was $1.54B, a 289% increase year-over-year.
  • Royalty Pharma plc annual Operating Income (Loss) for 2023 was $1.49B, a 386% increase from 2022.
  • Royalty Pharma plc annual Operating Income (Loss) for 2022 was $307M, a 78.5% decline from 2021.
  • Royalty Pharma plc annual Operating Income (Loss) for 2021 was $1.43B, a 10.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.49B +$1.19B +386% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $307M -$1.12B -78.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $1.43B -$165M -10.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $1.6B -$1.03B -39.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-15
2019 $2.62B +$1.26B +92.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $1.36B Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.